Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 47 | 47 | 17 | 51 | 0 |
| Cost of Goods | 95 | 61 | 66 | 120 | 0 |
| Gross Profit | -48 | -14 | -49 | -69 | 0 |
| Operating Expenses | 4,978 | 5,834 | 5,782 | 5,556 | 4,549 |
| Operating Income | -4,931 | -5,787 | -5,765 | -5,505 | -4,549 |
| Interest Expense | 0 | 0 | 526 | 113 | -24 |
| Other Income | -595 | -856 | 134 | 19 | 21 |
| Pre-tax Income | -5,526 | -6,643 | -6,157 | -5,599 | -4,504 |
| Income Tax | 3 | 4 | 6 | -8 | 4 |
| Net Income Continuous | -5,529 | -6,647 | -6,163 | -5,591 | -4,508 |
| Net Income | $-5,529 | $-6,647 | $-6,153 | $-5,591 | $-4,508 |
| EPS Basic Total Ops | -15.34 | -18.44 | -17.09 | -15.44 | -12.74 |
| EPS Basic Continuous Ops | -15.32 | -18.42 | -17.09 | -15.49 | -12.74 |
| EPS Diluted Total Ops | -15.34 | -18.44 | -17.09 | -15.44 | -12.74 |
| EPS Diluted Continuous Ops | -15.32 | -18.42 | -17.09 | -15.49 | -12.74 |
| EPS Diluted Before Non-Recurring Items | -15.29 | -18.44 | -17.09 | N/A | N/A |
| EBITDA(a) | $-3,879 | $-4,801 | $-5,033 | $-4,936 | $-4,486 |